|
|
MEDIA
December 1, 2009 PharmStar Pharmaceuticals, Inc. is engaged in the validation, manufacture, and continuous product improvement of AQUAPRIN, whose formulation and manufacture depend mainly upon considerable skill and "know-how." Of course, a number of patents have been applied for. Since the new patents, which we are 99% assure of will be granted within the next 12 months, the Company will enjoy 20 years of exclusive franchise. The company will also Initiate clinical trials, when funding permits, in order to meet FDA and FTC requirements to make marketing claims of “fastest acting, Safest, and most potent” analgesic on the market The Company
is leasing a 30,000 sq ft. facility at 3791 N. Wesleyan Blvd, Rocky Mount. All architectural and engineering
work for modifications have been completed and construction of the production facility is underway . This facility,
which has room for expansion for large scale production, houses the offices, R&D labs and pilot plant production capability.
The pilot plant will be FDA and CGMP compliant to provide for the manufacture of the products. Some pre-owned processing equipment
has already been purchased and additional equipment will be identified and purchased to provide the manufacturing capability
to meet forecast sales under the most stringent regulatory requirements. The Company possesses significant
product formulations and manufacturing know-how plus experience for the pharmaceutical products comprising its core business. December 5, 2009 Pharmstar announces that the company has been awarded
a grant of $336,000 for the updating of the facilities for producing Aquaprin. This grant has accelerated
the construction phase. |
